Information for shareholders only

The outcome of conversion of convertible debentures

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

The Board of Vironova AB (publ) ("Vironova" or the "Company") can today inform that a number of holders of convertible debentures have decided to convert their convertible loans to shares in the Company. The total amount of the different loans is SEK 73 Million and the loans will be converted on the share price of SEK 50 per share. The total amount of new shares that will be issued amounts to 1 460 000. Only series B shares will be issued. The convertible debentures were all originally issued on April 30th, 2020 following a decision by the board on September 18th, 2019.

Statement from the CEO

"During these unprecedented SARS-CoV-2 times across the globe, Vironova's focus remains on our customers, the researchers and others who need our support and access to our products and services". "This conversion of convertible loans to shares will further strengthen Vironovas capital base and it will enable the Company to focus and expand our commercial and research capabilities and deliver our innovative technologies to markets and partners around the world."

The outcome of the share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Dear shareholders and investors

The Board of Vironova AB (publ) ("Vironova" or the "Company") can today inform about the outcome of the directed issue of new shares of series A and B that was decided on November 23, 2020. The subscription period ended in December 2020 but due to the holiday season the board decided to extend the subscription period of the issue until January 8th, 2021. The issue has been fully subscribed and the record shows that the Company will receive approximately SEK 25 Million in cash before costs related to the issue. The total number of series A shares that has or will be registered amounts to 54 310 and the number of series B share that has or will be registered amounts to 445 760 giving a total of 500 070 new shares. Of that, a total number of 54 310 A shares and 258 791 B shares, has already been registered and the rest are soon to be registered.

Statement from the CEO

"During these unprecedented SARS-CoV-2 times across the globe, Vironovas focus remains on our customers, the researchers and others who need our support and access to our products and services", said Mohammed Homman, CEO and member of the board of Vironova.

"This round of financing and outcome of the rights issue, which has been completed in difficult market conditions, enables Vironova to focus and expand our commercial and research capabilities and deliver our innovative technologies to markets and partners around the world."

All the best
Investor Relations
Vironova AB